PXD 118490

Drug Profile

PXD 118490

Alternative Names: LEO 80140; PXD118490

Latest Information Update: 29 Mar 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CuraGen Corporation; TopoTarget
  • Class Antipsoriatics
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Psoriasis; Skin disorders

Most Recent Events

  • 23 Jan 2008 LEO Pharma discontinues development of PXD 118490; all rights to the compound revert to TopoTarget
  • 07 Nov 2006 Preclinical trials in Psoriasis in Europe (unspecified route)
  • 07 Nov 2006 Preclinical trials in Skin disorders in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top